1. In Vivo
  2. >>Market Access

Paying For Gene Therapy: Will Pharma Be First In Line?

 
• By Jennifer Tedaldi and Adriel Koschitzky

With 15 new gene and cell-based therapies in late-stage testing, the time is now to consider a critical strategic question: is there a pricing model for these budget-busting treatments that works in both safeguarding returns to innovators and providing access to patients at a price society is willing to pay? An analysis by ZS Associates looks at the options for biopharma going forward.

IV1806_Feat05-ZS_1200x675.jpg
Striking a balance: affordability versus innovation • Source: Shutterstock

The first-ever US gene and cell therapy approvals of 2017 suggest that the industry stands on the brink of a fundamental shift in the way transformative therapies will be financed and accessed by patients. In quick order that acknowledged the clinical merits of the science, the FDA approved the first directly administered gene therapy, Luxturna (voretigene neparvovec-rzyl), as well as the first two CAR-T therapies, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel).

What makes these therapies noteworthy is that we can call them potentially curative. They’re administered just once, or over a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By Leela Barham

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.

Q&A: Commercializing Oncology Products, Strategic Insights For Drug Developers

 
• By Jo Shorthouse

John Arena, president of Global Pharma Services at Cencora, talks to In Vivo about how companies can strategize market entry for oncology products.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

More from In Vivo

‘A Small Medtech Industry Ecosystem With An Outsized Global Influence’

 
• By Ashley Yeo

Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.